Study of a heart failure treatment using a combination drug consisting of reduced coenzyme Q10, astaxanthin, citrulline, and zinc

Study of a heart failure treatment using a combination drug consisting of reduced coenzyme Q10, astaxanthin, citrulline, and zinc - Study of a heart failure treatment using a combination drug consisting of reduced coenzyme Q10, astaxanthin, citrulline, and zinc

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020203

Enrollment

Registered

2015-12-15

Start date

2015-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

coenzyme Q10

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients with chronic heart failure (including DCM and OMI) who meet the following conditions: (1) LVEF < 40% (2) BNP level > 200 pg/mL (3) Plasma coenzyme Q10 concentrations < 950 ng/mL (4) Age >= 20 years (5) Patients who adequately understand the objectives and details of this study, and give a written informed consent

Exclusion criteria

Exclusion criteria: (1)Patients who meet the following criteria are excluded: those who have not completely recovered from a malignancy; with severe infection; suspected of having a pulmonary disease (including COPD) on a chest radiogram; who are on dialysis; and others who are found unacceptable at the discretion of the physician (2)Patients who have taken drugs or supplements including coenzyme Q10, astaxanthin, and citrulline within the last 2 months

Design outcomes

Primary

Measure	Time frame
1.BNP 2.QOL (6-min walk test, EQ-5D) 3.LVEF by echocardiography	—

Countries

Japan

Contacts

Public Contactsatomi kohata

A2 Healthcare Corporation Clinical Research Department

kohata-s@a2healthcare.com03-3830-1075

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026